EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma

Giulia Pasello, Daniela Scattolin, Eleonora Faccioli, Paolo Andrea Zucali, Giuseppe Marulli, Federica Grosso, Giovanni Luca Ceresoli, Marcello Tiseo, Alessandra Bearz, Fabiana Letizia Cecere, Luana Calabrò, Francesco Callegarin und 7 weitere

Clinical Lung Cancer · 2026-07 · 27 (6) · 31-35

DOI: 10.1016/j.cllc.2026.05.004 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Lung Cancer, 2026-07. Verfasst von Giulia Pasello und 18 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Pleural Neoplasms, Neoadjuvant Therapy, Mesothelioma. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Istituto Oncologico Veneto IRCCS, MSD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsPleural NeoplasmsNeoadjuvant TherapyMesotheliomaHumansPemetrexedAntibodies, Monoclonal, HumanizedCarboplatinCisplatinFemaleProspective StudiesPathologic Complete ResponseMalePrognosisMesothelioma, MalignantAgedMiddle AgedCombined Modality Therapy

Stichwörter der Autor:innen

ImmunotherapyMultimodalityPerioperativePleural MesotheliomaPleurectomy

Substanzen

PemetrexedAntibodies, Monoclonal, HumanizedCarboplatinCisplatinpembrolizumab

Autor:innen und Institutionen

  • Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. Electronic address: giulia.pasello@iov.veneto.it.
  • Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
  • Department of Cardiac, Thoracic, Vascular Science and Public Health, University of Padova, Padova, Italy.
  • Department of Oncology, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Thoracic Surgery Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Mesothelioma and Rare Cancers Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Förderung

  • Istituto Oncologico Veneto IRCCS
  • MSD

Zitieren

APA

Pasello, G., Scattolin, D., Faccioli, E., Zucali, P. A., Marulli, G., Grosso, F., Ceresoli, G. L., Tiseo, M., Bearz, A., Cecere, F. L., Calabrò, L., Callegarin, F., Del Bianco, P., De Salvo, G. L., Pezzuto, F., Calabrese, F., Guarneri, V., Dell'Amore, A., & Rea, F. (2026). CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma. Clinical Lung Cancer, 27(6), 31-35. https://doi.org/10.1016/j.cllc.2026.05.004

Vancouver

Pasello G, Scattolin D, Faccioli E, Zucali PA, Marulli G, Grosso F, et al. CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma. Clinical Lung Cancer. 2026;27(6):31-35. doi:10.1016/j.cllc.2026.05.004

BibTeX
@article{Pasello2026,
  author = {Pasello, Giulia and Scattolin, Daniela and Faccioli, Eleonora and Zucali, Paolo Andrea and Marulli, Giuseppe and Grosso, Federica and Ceresoli, Giovanni Luca and Tiseo, Marcello and Bearz, Alessandra and Cecere, Fabiana Letizia and Calabrò, Luana and Callegarin, Francesco and Del Bianco, Paola and De Salvo, Gian Luca and Pezzuto, Federica and Calabrese, Fiorella and Guarneri, Valentina and Dell'Amore, Andrea and Rea, Federico},
  title = {CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma},
  journal = {Clinical Lung Cancer},
  year = {2026},
  volume = {27},
  number = {6},
  pages = {31--35},
  doi = {10.1016/j.cllc.2026.05.004}
}
Kostenlos starten →